Kurs
0,00%
Kurs
0,00%
Open
28,00
High
29,42
Low
26,80
Close
28,00
Kursutveckling under dagen för detta pressmeddelande
(NOK).
Likviditet
12,3 MNOK
Likviditet
12,3 MNOK
Rel. mcap
1,56%
Antal aktier
445 742
Likviditet under dagen för detta pressmeddelande
Kalender
Tid* | ||
2026-02-25 | 06:30 | Bokslutskommuniké 2025 |
2025-11-26 | 00:10 | Kvartalsrapport 2025-Q3 |
2025-08-20 | 00:10 | Kvartalsrapport 2025-Q2 |
2025-05-22 | N/A | Årsstämma |
2025-05-14 | 00:10 | Kvartalsrapport 2025-Q1 |
2025-02-26 | 06:30 | Bokslutskommuniké 2024 |
2024-11-27 | - | Kvartalsrapport 2024-Q3 |
2024-08-21 | - | Kvartalsrapport 2024-Q2 |
2024-05-21 | - | X-dag ordinarie utdelning NYKD 0.00 NOK |
2024-05-16 | - | Årsstämma |
2024-05-14 | - | Kvartalsrapport 2024-Q1 |
2024-02-28 | - | Bokslutskommuniké 2023 |
2023-11-15 | - | Kvartalsrapport 2023-Q3 |
2023-08-23 | - | Kvartalsrapport 2023-Q2 |
2023-05-16 | - | Kvartalsrapport 2023-Q1 |
2023-05-12 | - | X-dag ordinarie utdelning NYKD 0.00 NOK |
2023-05-11 | - | Årsstämma |
2023-02-28 | - | Bokslutskommuniké 2022 |
2022-11-23 | - | Kvartalsrapport 2022-Q3 |
2022-08-24 | - | Kvartalsrapport 2022-Q2 |
2022-05-16 | - | Kvartalsrapport 2022-Q1 |
2022-05-13 | - | X-dag ordinarie utdelning NYKD 0.00 NOK |
2022-05-12 | - | Årsstämma |
2022-03-31 | - | Bokslutskommuniké 2021 |
2021-12-22 | - | Extra Bolagsstämma 2021 |
2021-11-17 | - | Kvartalsrapport 2021-Q3 |
2021-08-26 | - | Kvartalsrapport 2021-Q2 |
2021-05-12 | - | Kvartalsrapport 2021-Q1 |
2021-05-06 | - | X-dag ordinarie utdelning NYKD 0.00 NOK |
2021-05-05 | - | Årsstämma |
2021-04-21 | - | Bokslutskommuniké 2020 |
2020-11-17 | - | Kvartalsrapport 2020-Q3 |
2020-08-27 | - | Kvartalsrapport 2020-Q2 |
2020-07-07 | - | Split NYKD 1:5 |
2020-07-06 | - | Extra Bolagsstämma |
2020-05-12 | - | Kvartalsrapport 2020-Q1 |
2020-04-22 | - | Extra Bolagsstämma |
Beskrivning
Land | Norge |
---|---|
Lista | OB Match |
Sektor | Hälsovård |
Industri | Bioteknik |
2022-07-04 20:50:00
Oslo, Norway, July 4, 2022 - Nykode Therapeutics ASA (Oslo Stock Exchange (OSE):
NYKD), a clinical-stage biopharmaceutical company dedicated to the discovery and
development of vaccines and novel immunotherapies, today announced that 200,000
share options have been granted to Klaus Edvardsen in connection with his
appointment as Chief Development Officer. The share options will have a strike
price of NOK 31.11 per share, have a five-year term and will vest equally over a
four-year vesting period.
Please see further details in attached document.